Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.
Thomas Triomphe, executive VP, head of vaccines, Sanofi • Source: Sanofi
Sanofi is betting big on cutting-edge manufacturing and digital technologies as it broadens its vaccines innovation pipeline and gears alongside to ensure agility and flexibility in responding to the risk of future pandemics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Scrip about the latest developments.
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Scrip about the latest developments.
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
